ClinicalTrials.gg
CompletedNCT02463032Updated Dec 9, 2020Results posted

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

A Phase 2 interventional study of GTx-024 in ER+ and AR+ Breast Cancer, sponsored by GTx. Completed at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-09.

Sponsored by GTx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced Estrogen Receptor (ER)+ and Androgen Receptor (AR)+ breast cancer in postmenopausal women.

02

Conditions studied

  • ER+ and AR+ Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 136 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

GTx is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women (≥ 18 years of age) with or recurrent locally advanced BC, not amenable to curative treatment by surgery or radiotherapy, with objective evidence of disease progression.

    • Women must have received ≥ 1 prior hormonal treatment(s) in the metastatic or setting. If the most recent hormonal treatment was in the metastatic setting, duration of response (tumor regression or stabilization of disease) to this specific course of therapy must be ≥ 6 months. If the most recent hormonal treatment was in the adjuvant setting, duration of response (disease free) to this specific course of therapy must be ≥ 3 years
  • Histological or cytological confirmation of ER+ BC as assessed by a local laboratory using slides, paraffin blocks, or paraffin sample or by medical history: ER+ (confirmed as ER expression more than or equal to 1% positive tumor nuclei)
  • Human epidermal growth factor receptor 2 ()-negative tumor by local laboratory testing (immunohistochemistry [IHC] 0, 1+ regardless of fluorescence in situ hybridization [FISH] ratio; IHC 2+ with FISH ratio lower than 2.0 or HER2 gene copy less than 6.0; FISH ratio of 0, indicating gene deletion, when positive and negative in situ hybridization [ISH] controls are present)
  • Availability of paraffin embedded or formalin fixed tumor tissue; OR, a minimum of 10 and up to 20 slides of archived tumor tissue or new , if archived tissue is unavailable for central laboratory confirmation of AR status and molecular subtyping. Metastatic tumor tissue is preferred when possible.
  • women. Postmenopausal status is defined by the National Comprehensive Cancer Network as either:

    • Age ≥ 55 years and one year or more of amenorrhea
    • Age \< 55 years and one year or more of amenorrhea, with an estradiol assay \< 20 pg/mL
    • Age \< 55 years and surgical menopause with bilateral oophorectomy a. Note: Ovarian radiation or treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist (goserelin acetate or leuprolide acetate) is not permitted for induction of ovarian suppression at the time of screening. Long term use (>6 months prior to screening) is permitted
  • Radiological or clinical evidence (bone scan, computerized tomography [CT], and magnetic resonance Imaging [MRI]) of recurrence or progression within 30 days before randomization
  • Subject must have either or bone only non measurable disease, according to RECIST1.1
  • Adequate organ function as shown by:

    • (ANC) ≥ 1,500 cells/mm3
    • count ≥ 100,000 cells/mm3
    • (Hgb) ≥ 9.0 g/dL
    • Serum (AST) and alanine transaminase (ALT) ≤ 2.5 (ULN) (or ≤ 5 if hepatic metastases are present)
    • Total serum ≤ 2.0 × ULN (unless the subject has documented Gilbert Syndrome)
    • Alkaline phosphatase levels ≤ 2.5 × ULN (≤ 5 × ULN in subjects with liver metastasis)
    • Serum creatinine ≤ 2.0 mg/dL or 177 µmol/L
    • (INR), activated partial thromboplastin (aPTT), or partial thromboplastin time (PTT) \< 1.5 × ULN (unless on anticoagulant treatment at screening)
  • Subject has an (ECOG) performance status 0 or 1
  • Subjects with bone metastases should be treated with intravenous bisphosphonates or subcutaneous denosumab (or investigator preferred standard of care) prior to and/or during the trial, unless there is a or subject intolerance to these therapies. For patients who are normocalcemic, therapy can be initiated at the time the patient initiates study drug
  • Subject is able to swallow capsules
  • Able and willing to give voluntary, written and signed before any screening procedure and according to local guidelines

Exclusion criteria

Exclusion Criteria:

  • Previously received > 1 course of chemotherapy (not including immunotherapies or targeted therapies) for the treatment of

    a. Note: Subjects may have received 1 course of chemotherapy prior to surgery for the treatment of locally advanced disease and 1 course of chemotherapy for the treatment of metastatic BC; however, if surgery could not be performed, this will count as the 1 chemotherapy course allowed prior to study

  • Known to any of the GTx-024 components or subjects previously received treatment with SARM
  • Subjects with radiographic evidence of central nervous system (CNS) metastases as assessed by CT or MRI that are not well controlled (symptomatic or requiring control with continuous therapy [e.g., dexamethasone])

    a. Note: Subjects with are permitted to participate in the study if the CNS metastases are medically well-controlled and stable for at least 28 days after receiving local therapy (irradiation, surgery, etc.)

  • Radiotherapy within 14 days prior to randomization except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization. Subjects must have recovered from radiotherapy toxicities prior to randomization
  • Currently receiving hormone replacement therapy, unless discontinued prior to screening
  • Subjects positive for (HIV)
  • Subject has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases subject risk, in the opinion of the Investigator, such as but not limited to:

    • Myocardial infarction or arterial thromboembolic events within 6 months prior to Baseline or severe or unstable angina, (NYHA) Class III or IV disease, or a (corrected according to Bazett's formula) interval > 470 msec
    • Serious uncontrolled cardiac arrhythmia grade II or higher according to NYHA
    • Uncontrolled hypertension (systolic > 150 and/or diastolic > 100 mm Hg)
    • Acute and chronic, active infectious disorders and non malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy
    • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
    • Another active cancer (excluding adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ). Prior history of other cancer is allowed as long as there is no active disease within the prior 5 years
  • Major surgery within 28 days before randomization
  • Positive virus (HBV) and/or virus (HCV) infection at screening
  • History of non-compliance to medical regimens
  • Subjects unwilling to or unable to comply with the protocol
  • Subject is currently receiving treatment with any agent listed on the prohibited medication list
  • Treatment with any product within \< 4 half-lives for each individual investigational product OR 28 days prior to randomization
  • Current treatment with intravenous bisphosphonate or denosumab with elevated serum calcium corrected for albumin or ionized calcium levels outside institutional normal limits at screening
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    GTx-024 9 mg

    Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg

    Drug: GTx-024

  • Experimental
    GTx-024 18 mg

    Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg

    Drug: GTx-024

Interventions

  • To determine whether either or both doses result in an acceptable clinical benefit rate.

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects

    To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.

    Time frame: 24 weeks

Secondary outcomes

  1. Clinical Benefit Rate, in Full Analysis Set

    To estimate the clinical benefit response rate in all subjects randomized who receive at least one dose of study medication (the FAS) regardless of AR status as determined by the central laboratory. o estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.

    Time frame: 24 weeks

  2. Objective Response (CR + PR) in AR+ Patients

    To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.

    Time frame: 24 weeks

  3. Best Overall Response in AR+ Patients

    To estimate the best overall response of GTx-024 9 mg and 18 mg

    Time frame: From treatment initiation to end of treatment

  4. Progression Free Survival in All Subjects

    To estimate the progression free survival of subjects receiving Gtx-024 9 mg and 18 mg. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Subjects were assessed up through 24 months.

    Time frame: From randomization to tumor progression or death

  5. Time to Progression in All Subjects

    To estimate the time to progression in subjects receiving Gtx-024 9 mg and 18 mg in all subjects. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression was assessed up through 24 months.

    Time frame: From randomization to tumor progression or death

Other outcomes

  1. Number Subjects Experiencing Adverse Events

    To describe the safety profile of GTx-024 9 mg and 18 mg in all subjects randomized and treated. Reported adverse events were described by system organ class (SOC) as opposed to individual events

    Time frame: Up to 24 months

07

Results

Posted Dec 9, 2020

Participant flow

Participant flow — Overall Study
MilestoneGTx-024 9 mgGTx-024 18 mg
Started7264
Completed10
Not completed7164
Withdrew: Lack of efficacy6150
Withdrew: Death88
Withdrew: Adverse event26

Outcome measures

PrimaryClinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects

To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.

Time frame:
24 weeks
Reported as:
Number · participants
Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects
participantsGTx-024 9 mgGTx-024 18 mg
Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects1615
SecondaryClinical Benefit Rate, in Full Analysis Set

To estimate the clinical benefit response rate in all subjects randomized who receive at least one dose of study medication (the FAS) regardless of AR status as determined by the central laboratory. o estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.

Time frame:
24 weeks
Reported as:
Number · participants
Clinical Benefit Rate, in Full Analysis Set
participantsGTx-024 9 mgGTx-024 18 mg
Clinical Benefit Rate, in Full Analysis Set1817
SecondaryObjective Response (CR + PR) in AR+ Patients

To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.

Time frame:
24 weeks
Reported as:
Number · participants
Objective Response (CR + PR) in AR+ Patients
participantsGTx-024 9 mgGTx-024 18 mg
PR22
CR20
SecondaryBest Overall Response in AR+ Patients

To estimate the best overall response of GTx-024 9 mg and 18 mg

Time frame:
From treatment initiation to end of treatment
Reported as:
Number · participants
Best Overall Response in AR+ Patients
participantsGTx-024 9 mgGTx-024 18 mg
PR22
CR20
SecondaryProgression Free Survival in All Subjects

To estimate the progression free survival of subjects receiving Gtx-024 9 mg and 18 mg. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Subjects were assessed up through 24 months.

Time frame:
From randomization to tumor progression or death
Reported as:
Median · months
Progression Free Survival in All Subjects
monthsGTx-024 9 mgGTx-024 18 mg
Progression Free Survival in All Subjects5.3 (NA to NA)2.9 (NA to NA)
SecondaryTime to Progression in All Subjects

To estimate the time to progression in subjects receiving Gtx-024 9 mg and 18 mg in all subjects. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression was assessed up through 24 months.

Time frame:
From randomization to tumor progression or death
Reported as:
Median · months
Time to Progression in All Subjects
monthsGTx-024 9 mgGTx-024 18 mg
Time to Progression in All Subjects5.3 (NA to NA)2.9 (NA to NA)
Other pre-specifiedNumber Subjects Experiencing Adverse Events

To describe the safety profile of GTx-024 9 mg and 18 mg in all subjects randomized and treated. Reported adverse events were described by system organ class (SOC) as opposed to individual events

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number Subjects Experiencing Adverse Events
ParticipantsGTx-024 9 mgGTx-024 18 mg
Number Subjects Experiencing Adverse Events7156

Adverse events

Collected over 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GTx-024 9 mg8/72 (11.1%)6/72 (8.3%)71/72 (98.6%)
GTx-024 18 mg8/64 (12.5%)10/64 (15.6%)56/64 (87.5%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventGTx-024 9 mgGTx-024 18 mg
hypercalcemiaInvestigations1/724/64
cardiac failureCardiac disorders0/722/64
sepsisInfections and infestations2/722/64
tumor flareInvestigations0/722/64
increased serum creatinineInvestigations0/721/64
acute kidney failureRenal and urinary disorders1/721/64
anemia and marrow failureBlood and lymphatic system disorders0/721/64
painMusculoskeletal and connective tissue disorders1/721/64
pneumoniaInfections and infestations0/721/64
gastritisGastrointestinal disorders0/721/64
Most frequent other events
Most frequent other events
EventGTx-024 9 mgGTx-024 18 mg
GI disorderGastrointestinal disorders25/7218/64
general disorderGeneral disorders25/7212/64
investigationsInvestigations17/7215/64
musculoskeletalMusculoskeletal and connective tissue disorders11/7212/64
metabolismMetabolism and nutrition disorders8/7211/64
nervous systemNervous system disorders10/727/64
skinSkin and subcutaneous tissue disorders6/728/64

Baseline characteristics

Age, Continuous
Age, Continuous(years)GTx-024 9 mgGTx-024 18 mgTotal
Median61 (35 to 83)62 (33 to 81)61 (33 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)GTx-024 9 mgGTx-024 18 mgTotal
Female7264136
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GTx-024 9 mgGTx-024 18 mgTotal
Hispanic or Latino000
Not Hispanic or Latino7059129
Unknown or Not Reported257
Androgen Receptor (AR) status positive
Androgen Receptor (AR) status positive(Participants)GTx-024 9 mgGTx-024 18 mgTotal
Count of participants5052102
08

Study locations

4 sites
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • St. Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • The West Clinic, PC
    Memphis, Tennessee 38120, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Mar 2019, 43 months.

Results were first posted in Dec 2020, 1 year 9 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 43 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2015
First posted
Jun 4, 2015
StartActual
Aug 2015
Primary completionActual
Mar 2019
CompletionActual
Mar 2019
Results first posted
Dec 9, 2020
Last update
Dec 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02463032
Lead sponsor
GTx
Responsible party
Sponsor
First posted
Jun 4, 2015
Start date
Aug 2015
Primary completion
Mar 2019
Completion
Mar 2019
Results posted
Dec 9, 2020
Last update
Dec 9, 2020

Study contacts

Beth A Overmoyer, MD
principal investigator · Susan Smith Center for Women's Cancers, Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ostarine

Start the discussion